|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 463 JPY | +3.12% |
|
+1.31% | -19.90% |
| 09/05 | StemRIM to Seek Shareholders' Approval on Capital Stock Reduction | MT |
| 13/03 | StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy | CI |
StemRIM Inc. announced the commencement, from April 10, 2023, of a global Phase II trial of Redasemtide in patients with acute ischemic stroke. This developmental milestone was achieved after receiving approval from PMDA, in response to a clinical trial plan submitted by Shionogi & Co. Ltd. on March 27, 2023.
Originally, a global Phase III trial was planned, but, for the purpose of dose setting, a global Phase II trial was chosen instead.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.90% | 18Cr | |
| -2.29% | 8.99TCr | |
| -3.95% | 3.76TCr | |
| -13.07% | 3.28TCr | |
| +63.05% | 2.65TCr | |
| -22.14% | 1.43TCr | |
| -7.96% | 1.3TCr | |
| -9.33% | 1.19TCr | |
| -46.33% | 1.08TCr | |
| +5.77% | 911.12Cr |
STEMRIM 
